Pharma BD Deal Intelligence
Merck's $3.85B acquisition of Idenix Pharmaceuticals for its hepatitis C pipeline turned into a bust, with the assets never converting into an approved therapy amid a hepatitis C market that Gilead's Sovaldi and Harvoni had already locked up.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Merck acquired Idenix Pharmaceuticals for $3.85B, a hepatitis C drug developer.
Merck took a $2.9 billion impairment charge on the hepatitis C drug uprifosbuvir inherited from the $3.85 billion Idenix acquisition, raising questions about…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Merck acquired Idenix Pharmaceuticals for $3.85B, a hepatitis C drug developer.
30K US cases/yr · $20.0B Global HCV Market (2015 peak)
The HCV market was in the midst of a revolution in 2014. Gilead's Sovaldi (sofosbuvir, approved Dec 2013) and Harvoni (ledipasvir/sofosbuvir, Oct 2014) transformed HCV from a chronic disease to a curable one. Merck acquired Idenix for $3.85B to build its own nucleotide polymerase inhibitor program, seeking to compete in this exploding market.
Gilead dominated with Sovaldi/Harvoni ($19.1B combined 2015 sales). AbbVie launched Viekira Pak (2014), and BMS had daclatasvir. Merck's own Zepatier (elbasvir/grazoprevir) launched in 2016 but achieved only modest share (~$1B peak). The Idenix acquisition was widely criticized as overpaying for a pipeline that never produced a major product, as Merck's nucleotide program from Idenix was discontinued due to safety concerns.
Merck completed $3.85B acquisition of Idenix Pharmaceuticals, gaining hepatitis C candidates IDX21437 and samatasvir to compete in the HCV market.
Merck recorded $2.9B charge on uprifosbuvir (MK-3682), estimating remaining value at just $240M as HCV market contracted sharply under Gilead dominance.
Merck took $2.9B write-down on key asset as HCV market collapsed. The $3.85B deal generated minimal returns, ranking among Merck's worst M&A bets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Idenix Pharmaceuticals (this deal) | 2014 | $3.9B | 15 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2014 deals · Merck & Co. Inc. deals · Infectious Disease deals